Otonomy Company Profile (NASDAQ:OTIC)

Analyst Ratings

Consensus Ratings for Otonomy (NASDAQ:OTIC) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $32.40 (119.22% upside)

Analysts' Ratings History for Otonomy (NASDAQ:OTIC)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/9/2015Bank of America Corp.UpgradeNeutral -> Buy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015JPMorgan Chase & Co.Initiated CoverageHold$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Sanford C. BernsteinUpgradeMarket Perform -> Outperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2015SunTrust Banks Inc.Initiated CoverageBuy$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2015Cowen and CompanyInitiated CoverageOutperform$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2014Barrington ResearchInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Otonomy (NASDAQ:OTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Otonomy (NASDAQ:OTIC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.79)($0.79)($0.79)
Q2 20161($0.92)($0.92)($0.92)
Q3 20161($0.93)($0.93)($0.93)
Q4 20161($0.96)($0.96)($0.96)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Otonomy (NASDAQ:OTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Otonomy (NASDAQ:OTIC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Otonomy (NASDAQ:OTIC)
DateHeadline
07/23/16 09:37 AMEquity Roundup: Stock Performance Focus on Otonomy, Inc. (NASDAQ:OTIC) - Press Telegraph
07/21/16 06:00 PMOtonomy Incorporated (NASDAQ:OTIC) Short Interest Increased By 11.52% - Press Telegraph
07/21/16 06:00 PMOtonomy, Inc. (NASDAQ:OTIC): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:34 AMOtonomy, Inc. (NASDAQ:OTIC) Updated Price Targets - FTSE News
07/20/16 08:34 AMIs $55 Price Target Attainable For Otonomy, Inc. (NASDAQ:OTIC)? - Investor Newswire
07/20/16 07:18 AMOtonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : July 20, 2016 -
07/18/16 11:07 AMShares Moving Down on the Week: Otonomy, Inc. (NASDAQ:OTIC) - Engelwood Daily
07/18/16 11:07 AMOtonomy, Inc. (NASDAQ:OTIC) Broker Price Targets For The Coming Week - Fiscal Standard
07/18/16 11:07 AMOtonomy, Inc. (NASDAQ:OTIC) Wall Street Analyst Recommendation Outlook - TGP
07/16/16 08:59 AMShares Experiencing a Downtrend: Otonomy, Inc. (NASDAQ:OTIC) - TGP
07/15/16 04:45 PMIncreased Volatility Noted on Shares of: Otonomy, Inc. (NASDAQ:OTIC) - Engelwood Daily
07/13/16 08:38 AMStrong Sell Calls For Otonomy, Inc. (NASDAQ:OTIC) At 0 - Investor Newswire
07/12/16 09:59 AMOtonomy (NASDAQ:OTIC) Institutional Investors Quarterly Sentiment - Press Telegraph
07/11/16 05:40 PMOtonomy Incorporated (NASDAQ:OTIC) Short Interest Decreased By 1.64% - Consumer Eagle
07/11/16 10:22 AMWall Street Ratings and Target Price Views on Otonomy, Inc. (NASDAQ:OTIC) - Telanagana Press
07/10/16 09:48 AMWere Analysts Bearish Otonomy Inc (NASDAQ:OTIC) This Week? - Press Telegraph
07/08/16 05:45 PMBroker Outlook For Otonomy, Inc. (NASDAQ:OTIC) - Fiscal Standard
07/07/16 05:43 PMCan Otonomy, Inc. (NASDAQ:OTIC) Improve on the Earnings Front? - Engelwood Daily
07/07/16 05:43 PMHeightened Volatility Check on: Otonomy, Inc. (NASDAQ:OTIC) - Engelwood Daily
07/07/16 05:43 PMOtonomy Incorporated (NASDAQ:OTIC) Short Interest Decreased By 1.64% - Press Telegraph
07/06/16 10:20 AMStock Tracking Down This Month; Investor Alert on Otonomy, Inc. (NASDAQ:OTIC) - Engelwood Daily
07/05/16 05:28 PMShare Volatility in Focus: Otonomy, Inc. (NASDAQ:OTIC) - Engelwood Daily
07/05/16 05:28 PMOtonomy, Inc. (NASDAQ:OTIC) Expected to Reach Highs Of $55 - Investor Newswire
07/03/16 09:53 AMWere Analysts Bullish Otonomy Inc (NASDAQ:OTIC) This Week? - Press Telegraph
06/30/16 05:57 PMNew Broker Ratings For Otonomy, Inc. (NASDAQ:OTIC) - FTSE News
06/29/16 08:31 AMNext Weeks Broker Price Targets For Otonomy, Inc. (NASDAQ:OTIC) - Fiscal Standard
06/27/16 05:43 PMAchaogen Inc : Biotech Comeback Kids
06/27/16 05:42 PMBiotech Comeback Kids
06/23/16 08:22 AMStrong Buy Calls Count For Otonomy, Inc. (NASDAQ:OTIC) At 4 - Investor Newswire
06/23/16 08:22 AMRecently Issued Stock Ratings For Otonomy, Inc. (NASDAQ:OTIC) - Fiscal Standard
06/22/16 03:32 PMOTONOMY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 07:18 AMThis Weeks Broker Views For Otonomy, Inc. (NASDAQ:OTIC) - Fiscal Standard
06/16/16 09:54 AMMarket Movers: Verastem, Inc. (NASDAQ:VSTM), Otonomy, Inc. (NASDAQ:OTIC), Helios and Matheson Analytics Inc ... - KC Register
06/11/16 08:32 AMOtonomy (OTIC) Enrolls First Patient in Single OTIPRIOTM Phase 3 cTrial
06/09/16 06:49 AMOtonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa - [at noodls] - SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
06/08/16 06:04 PMOTONOMY INC. (NASDAQ:OTIC) Financial Condition Compared to S&P 500 - CML News
06/04/16 05:44 PMAre Analysts Bearish Otonomy Inc (NASDAQ:OTIC) After Last Week? - HNN
06/03/16 08:35 AMWallachBeth Initiates Coverage on Otonomy Inc to Buy - Trade Calls - WallachBeth Initiates Coverage on Otonomy Inc to BuyTrade CallsWallachBeth Initiates Coverage on Otonomy Inc(NASDAQ:OTIC). The shares have been rated Buy. The rating by WallachBeth was issued on May 26, 2016. Otonomy Inc (OTIC) made into the market gainers list on Wednesdays trading session with the shares ...
06/02/16 06:04 PMStock Review and Earnings Check on Otonomy, Inc. (NASDAQ:OTIC) - HNN - Stock Review and Earnings Check on Otonomy, Inc. (NASDAQ:OTIC)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Otonomy, Inc. (NASDAQ:OTIC) to ...and more »
06/02/16 06:04 PMOtonomy, Inc. (NASDAQ:OTIC) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Otonomy, Inc. (NASDAQ:OTIC) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Otonomy, Inc. (NASDAQ:OTIC). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Stock in a Downward Trend: Otonomy, Inc. (NASDAQ:OTIC)Franklin IndependentCurrent Price Targets For Otonomy, Inc. (NASDAQ:OTIC)Risers & FallersOtonomy, Inc. (NASDAQ:OTIC): Price Target ProjectionsNews TribuneThe Postall 5 news articles »
06/02/16 08:40 AMNews Sentiment For Otonomy, Inc. (NASDAQ:OTIC) - Investor Newswire - News Sentiment For Otonomy, Inc. (NASDAQ:OTIC)Investor NewswireOtonomy, Inc. (NASDAQ:OTIC) Average broker stands at 1.4 while it was 1.4 three months ago. The quarterly report of Otonomy, Inc. (NASDAQ:OTIC) can be made public close to 2016-08-10. It is estimated by the recent update released by the company.and more »
06/01/16 07:16 AMOtonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : June 1, 2016 -
05/31/16 10:19 AMShare Rating Focus on Otonomy, Inc. (NASDAQ:OTIC) - HNN - Share Rating Focus on Otonomy, Inc. (NASDAQ:OTIC)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.4 on shares of Otonomy, Inc. (NASDAQ:OTIC). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
05/30/16 12:39 PMOtonomy Incorporated (NASDAQ:OTIC) Sellers Covered 0.39% of Their Shorts - HNN - Otonomy Incorporated (NASDAQ:OTIC) Sellers Covered 0.39% of Their ShortsHNNThe short interest to Otonomy Incorporated's float is 9.31%. The stock increased 0.84% or $0.12 on May 27, hitting $14.33. About 107,751 shares traded hands. Otonomy Inc (NASDAQ:OTIC) has declined 30.13% since October 22, 2015 and is downtrending.and more »
05/30/16 12:39 PMOtonomy, Inc. (NASDAQ:OTIC) Broker Price Targets For The Coming Week - Share Trading News - Otonomy, Inc. (NASDAQ:OTIC) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Otonomy, Inc. (NASDAQ:OTIC). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Weekly Research Analysts' Ratings Updates for Otonomy (OTIC)Let Me Know About Thisall 2 news articles »
05/27/16 11:45 AMEarnings Review and Stock Rundown for Otonomy, Inc. (NASDAQ:OTIC) - Wall Street Hints and News - Earnings Review and Stock Rundown for Otonomy, Inc. (NASDAQ:OTIC)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Otonomy, Inc. (NASDAQ:OTIC) to post ...and more »
05/26/16 08:58 AMCoverage initiated on Otonomy by WallachBeth -
04/18/16 06:41 AMOtonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA - [at noodls] - SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
04/08/16 10:28 AMEdited Transcript of OTIC earnings conference call or presentation 7-Mar-16 9:30pm GMT -
04/05/16 07:47 AMWhy You Shouldn't Bet Against Otonomy (OTIC) Stock -

Social

About Otonomy

Otonomy logoOtonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company's product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OTIC
  • CUSIP:
Key Metrics:
  • Previous Close: $14.78
  • 50 Day Moving Average: $15.32
  • 200 Day Moving Average: $15.03
  • P/E Ratio: N/A
  • P/E Growth: -0.20
  • Market Cap: $445.07M
  • Beta: 3.2
  • Current Year EPS Consensus Estimate: $-3.56 EPS
  • Next Year EPS Consensus Estimate: $-3.19 EPS
Additional Links:
Otonomy (NASDAQ:OTIC) Chart for Wednesday, July, 27, 2016